IMRN Immuron Limited

1.090USD+0.93%Mkt Cap: 8.80M $P/E: —

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the Unit…

Key Statistics

Company
Market Cap8.80M USD
Enterprise Value-151.73K USD
Revenue (TTM)7.71M USD
Gross Profit4.98M USD
Net Income (TTM)-3.68M USD
Revenue/Share1.04 USD
Last Price1.090 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-108.00
PEG—
EV/EBITDA0.04
EV/Revenue-0.02
P/S1.13
P/B1.11
EPS (TTM)-0.34
EPS (Forward)-0.01
52W Range
0.677024% of range2.390
52W High2.390 USD
52W Low0.6770 USD
Profitability
Gross Margin64.50%
Oper. Margin-45.12%
EBITDA Margin-45.68%
Profit Margin-47.71%
ROE-38.27%
ROA-19.14%
Growth
Revenue Growth7.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.26M USD
CapEx (TTM)—
FCF Margin-26.84%
FCF Yield-23.53%
Net Debt-8.83M USD
Net Debt/EBITDA2.51
Balance Sheet
Debt/Equity0.01
Current Ratio7.26
Quick Ratio5.84
Book Value/Sh0.97 USD
Cash/Share1.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.899 USD
Upside (mean)+257.7%
Target Range3.899 USD – 3.899 USD
# Analysts1
Ownership
Shares Out.8.07M
Float7.14M
Insiders0.00%
Institutions0.97%
Short Interest
Short Ratio0.0d
Short % Float2.25%
Short % Out.1.43%
Shares Short115.69K
Short (prev mo.)39.94K
Technical
SMA 501.195 (-8.8%)
SMA 2001.006 (+8.4%)
Beta0.47
S&P 52W Chg15.78%
Avg Vol (30d)4.30M
Avg Vol (10d)87.23K
Technical Indicators
RSI (14)41.6
MACD-0.0460
MACD Signal-0.0205
MACD Hist.-0.0256
BB Upper1.728 USD
BB Middle1.276 USD
BB Lower0.8250 USD
BB Width70.72%
ATR (14)0.0985 USD
Vol Ratio (20d)0.01x